Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Cancer Prev Res (Phila). 2009 May 26;2(6):538–545. doi: 10.1158/1940-6207.CAPR-09-0063

Figure 1.

Figure 1

Inhibition of erlotinib-induced cell cycle regulatory protein p21 and p27 by EGCG. (A) Tu686 (B) 1986LN (C) 886LN and (D) SQCCY1 cells were treated with 30 μM EGCG (E), 0.5 μM erlotinib (ER) or a combination of 30 μM EGCG and 0.5 μM erlotinib (C) for the indicated times. Total cell lysates were immunoblotted with anti-p27 (Santa Cruz) and anti-p21 (Santa Cruz). NT is untreated cells. Reproducibility of the data were confirmed with at least three independent experiments for each cell lines.